TITLE

Randomized Clinical Study of a Histamine H3 Receptor Antagonist for the Treatment of Adults with Attention-Deficit Hyperactivity Disorder

AUTHOR(S)
Weisler, Richard H.; Pandina, Gahan J.; Daly, Ella J.; Cooper, Kimberly; Gassmann-Mayer, Cristiana
PUB. DATE
May 2012
SOURCE
CNS Drugs;2012, Vol. 26 Issue 5, p421
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Psychostimulants, including methylphenidate and amphetamine preparations, are commonly prescribed for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adults. Histamine H3 recep-tors reside on non-histamine neurons and regulate other neurotransmitters (e.g. acetylcholine, noradrenaline [norepinephrine]) suggesting that H3 an-tagonists have the potential to improve attention and impulsivity. Research indicates that H3 receptor antagonists due to their novel mechanism of action may have a unique treatment effect offering an important alternative for the treatment of ADHD. Bavisant (JNJ-31001074) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD. Objective: The objective of this study was to evaluate the efficacy, safety and tolerability of three dosages of bavisant compared with placebo in adults with ADHD. Study design: This randomized, double-blind, placebo- and active-controlled, parallel-group, multicentre study evaluated three dosages of bavisant (1 mg/day, 3mg/day or 10mg/day) and two active controls in adults with ADHD. The study consisted of a screening phase of up to 14 days, a 42-day double-blind treatment phase and a 7-day post-treatment follow-up phase. Efficacy and safety assessments were performed. Setting: The study was conducted at 37 study centres in the US from April 2009 through January 2010. Participants: Men and women aged 18-55 years with an established diagnosis of ADHD as confirmed by clinician and self-report diagnostic measures were enrolled. Intervention: Participant s were randomly assigned equally to one of six treat-ment groups: placebo, bavisant 1 mg/day, 3 mg/day or 10 mg/day, atomoxetine hydrochloride 80 mg/day or osmotic-release oral system (OROS) methyl-phenidate hydrochloride 54 mg/day. Main outcome measure: The primary efficacy endpoint was the change in the Attention Deficit Hyperactivity Disorder Rating Scale, Version IV (ADHD-RS-IV) total score from baseline (day 1) to the end of the treatment phase (day 42), and included all randomized participants who received one or more doses of study drug and had baseline and one or more post-baseline assess-ments (intent-to-treat [ITT] population). Safety assessments included treat-ment-emergent adverse events (TEAEs), laboratory tests and ECG readings. Results: 430 participants were randomized, 424 received one or more doses of study medication and 335 (78%) of those randomized completed the study. Study participants had a mean age of 33.9 years and were predominantly White men. Mean treatment duration ranged from 31.4 to 38.8 days across groups. Mean change from baseline in the total ADHD-RS-IV score at day 42 (primary efficacy endpoint) was -8.8 in the placebo group versus -9.3, --11.2 and -12.2 in the bavisant 1 mg/day, 3 mg/day and 10 mg/day groups, respectively; the change in the 10 mg/day group was not statistically superior to placebo (p = 0.161), and hence statistical comparisons of the 1 mg/day and 3 mg/day groups with placebo based on a step-down closed testing procedure were not performed. Mean change from baseline in the total ADHD-RS-IV score at day 42 was superior to placebo in the atomoxetine (-15.3) and OROS methylphenidate (-15.7) groups (p< 0.005). Secondary efficacy assessments demonstrated a similar pattern with a non-significant trend towards im-provement in the bavisant groups. The two lower dosages showed a good tolerability profile, but the higher dosage of bavisant was less well tolerated, as evidenced by the incidence of total TEAEs (61.8%, 82.4%, 89.0%), and discontinuations due to TEAEs (4.4%, 7.4%, 19.2%) in the bavisant 1 mg/day, 3 mg/day and 10 mg/day groups, respectively, compared with 58.9% and 2.7%, respectively on placebo. In the atomoxetine and OROS methylpheni-date groups, the incidence of total TEAEs was 83.8% and 82.4% and dis-continuations due to TEAEs was 10.8% and 8.8%, respectively. Conclusion: Bavisant, a highly selective, wakefulness-promoting Conclusion: Bavisant, a highly selective, wakefulness-promoting H3 antag-onist, did not display significant clinical effectiveness in the treatment of adults with ADHD.
ACCESSION #
76477732

 

Related Articles

  • The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Bouffard, Rachelle; Hechtman, Lily; Minde, Klaus; Iaboni-Kassab, Fiorella // Canadian Journal of Psychiatry;Sep2003, Vol. 48 Issue 8, p546 

    Objective: To evaluate the efficacy of methylphenidate in treating adults with attention-deficit hyperactivity disorder (ADHD), using subjective (self-report) and objective (computerized test) measures.Method: This double-blind crossover trial of placebo vs...

  • Differential roles for cortical versus sub-cortical noradrenaline and modulation of impulsivity in the rat. Benn, Abigail; Robinson, Emma // Psychopharmacology;Jan2017, Vol. 234 Issue 2, p255 

    Rationale: Atomoxetine is a noradrenaline re-uptake inhibitor licensed for the treatment of adult and childhood attention deficit hyperactivity disorder. Although atomoxetine has established efficacy, the mechanisms which mediate its effects are not well understood. Objectives: In this study, we...

  • Health-Related Quality of Life and Functional Outcomes from a Randomized, Controlled Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention Deficit Hyperactivity Disorder. Banaschewski, Tobias; Soutullo, César; Lecendreux, Michel; Johnson, Mats; Zuddas, Alessandro; Hodgkins, Paul; Adeyi, Ben; A. Squires, Liza; Coghill, David // CNS Drugs;2013, Vol. 27 Issue 10, p829 

    Background: Optimal management of attention deficit hyperactivity disorder (ADHD) aims not only to ameliorate patients’ symptoms, but also to improve health-related quality of life (HRQL) and functioning. A pivotal, 7-week, randomized, double-blind, placebo-controlled, phase III study in...

  • Attention-deficit hyperactivity disorder in adults.  // British Journal of Hospital Medicine (17508460);Jun2008, Vol. 69 Issue 6, p317 

    The article reports on the European Long-Acting Methylphenidate in Adult ADHD or LAMDA trial that was designed to investigate the safety and efficacy of three fixed doses of prolonged-release OROS methylphenidate. Overall, it was found that the treatment resulted into a substantially greater...

  • Methylphenidate.  // Reactions Weekly;9/18/2010, Issue 1319, p32 

    The article describes the cases of three patients who presented with psychotic symptoms while receiving treatment with methylphenidate for attention-deficit/hyperactivity disorder (ADHD), referencing a study published in the August 2010 issue of the journal "Clinical Neuropharmacology."

  • Attention deficit hyperactivity disorder or hyperkinetic disorder in adults. Toone, B. K.; Van Der Linden, G. J. H.; van der Linden, G J // British Journal of Psychiatry;Jun97, Vol. 170, p489 

    The article highlights attention deficit hyperactivity disorder (ADHD) or hyperkinetic disorder in adults. It discusses the etiology, epidemiology, assessment and diagnosis, and long-term outcome of ADHD. It also focuses on neuropsychological testing in adult ADHD as well as pharmacologic...

  • A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. R�sler, Michael; Fischer, Roland; Ammer, Richard; Ose, Claudia; Retz, Wolfgang // European Archives of Psychiatry & Clinical Neuroscience;Mar2009, Vol. 259 Issue 2, p120 

    Attention-deficit/hyperactivity disorder (ADHD) affects many adults who had ADHD in childhood. Although stimulants and methylphenidate in particular are a common off-label treatment for adult patients with ADHD in European countries, little is known about their long-term efficacy and safety. A...

  • Methylphenidate significantly improves declarative memory functioning of adults with ADHD. Verster, Joris C.; Bekker, Evelijne M.; Kooij, J. J.; Buitelaar, Jan K.; Verbaten, Marinus N.; Volkerts, Edmund R.; Olivier, Berend // Psychopharmacology;Oct2010, Vol. 212 Issue 2, p277 

    Background: Declarative memory deficits are common in untreated adults with attention-deficit hyperactivity disorder (ADHD), but limited evidence exists to support improvement after treatment with methylphenidate. The objective of this study was to examine the effects of methylphenidate on...

  • Use of desipramine for treatment of adult ADHD. Apgar, Barbara // American Family Physician;1/1/1997, Vol. 55 Issue 1, p306 

    Summarizes a study by T.E. Wilens, et al, in the 1996 issue of the `American Journal of Psychiatry' volume 153, which evaluated the effectiveness of desipramine in adult patients with attention deficit hyperactivity disorder (ADHD). Background on the study; Classification of the ADHD group...

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics